HTCR - HeartCore Signs 13th Go IPO Contract | Benzinga
NEW YORK and TOKYO, March 18, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (NASDAQ:HTCR) ("HeartCore" or the "Company"), a leading enterprise software and consulting services company based in Tokyo, announced that it has signed an agreement ("Consulting Agreement") with PharmaBio Corporation ("PharmaBio") for its 13th Go IPO consulting service win.
As compensation for its services, HeartCore expects to generate from PharmaBio an aggregate of $500,000 in initial fees and $300,000 in success fees. In addition, HeartCore has received a warrant to acquire 3% of PharmaBio's common stock, on a fully diluted basis.
"I am pleased to announce our 13th Go IPO contract win and our second contract for 2024," said HeartCore CEO Sumitaka Kanno Yamamoto. "With the recent $9 million generated from the sale of a Go IPO client's warrant, this business remains a pivotal driver for our long-term financial growth and our ability to pursue M&A opportunities within our software business. As our clients achieve successful listings on U.S. exchanges, HeartCore is poised to reach new heights, fueled by the revenue influx from the post-IPO sale of additional Go IPO client warrants. Our team's reputation and services continue to solidify, establishing us as the preferred, go-to U.S. IPO advisory firm within the Japanese markets. We look forward to announcing our client's ...